Health care costs among individuals with chronic obstructive pulmonary disease within several large, multi-state employers

Journal of Occupational and Environmental Medicine

Volumn 50, Issue 10, 2008, Pages 1130-1138

  Darkow, Theodore ^a   Chastek, Benjamin J ^a   Shah, Hemal ^b   Phillips, Amy L ^b  

^a Health Economics and Outcomes Research   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE;

EID: 56049097941     PISSN: 10762752     EISSN: None     Source Type: Journal    
DOI: 10.1097/JOM.0b013e31818837c8     Document Type: Article

References (25)

1. Celli BR. MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Resp J. 2004;23:932-946.
2. Chronic Obstructive Pulmonary Disease: Data Fact Sheet. US Department of Health and Human Services, National Institutes of Health, NHLBI, NIH Publication 03-5229, March 2003.
3. World Health Organization. Chronic respiratory diseases: COPD. Available at: www.who.int/respiratory/copd/en/. Accessed December 2005.
4. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. MMWR Surveill Summ. 2002;51:1-16.
5. Minkoff NB. Analysis of the current care model of the COPD patient: a health outcomes assessment and economic evaluation. J Manag Care Pharm. 2005;11(6 Suppl A):S3-S7.
6. Tinkelman D, Corsello P. Chronic obstructive pulmonary disease: the impact occurs earlier than we think. Am J Manag Care. 2003;9:767-771.
7. Halpern MT, Stanford RH, Borker R. The burden of COPD in the U.S.A.: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S81-S89.
8. Wang PS, Beck A, Berglund P, et al. Chronic medical conditions and work performance in the health and work performance questionnaire calibration surveys. J Occup Environ Med. 2003;45:1303-1311.
9. Goetzel RZ, Hawkins K, Ozminkowski RJ, Wang S. The health and productivity cost burden of the "Top 10" physical and mental health conditions affecting six large U.S. employers in 1999. J Occup Environ Med. 2003;45:5-14.
10. Darkow T, Kadlubek PJ, Shah H, Phillips AL, Marion JP. A retrospective analysis of disability and its related costs among employees with chronic obstructive pulmonary disease. J Occup Environ Med. 2007;49:22-30.
11. Mapel DW, Hurley JS, Frost FJ, Petersen HV, Picchi MA, Coultas DB. Health care utilization in chronic obstructive pulmonary disease: a case-control study in a health maintenance organization. Arch Intern Med. 2000;160:2653-2658.
12. Tinkelman DG, George D, Halbert IU. Chronic obstructive pulmonary disease in patients under age 65: utilization and costs from a managed care sample. J Occup Environ Med. 2005;47:1125-1130.
13. Yu-Isenberg KS, Vanderplas A, Chang EY, Shah H. Utilization and medical care expenditures in patients with chronic obstructive pulmonary disease: a managed care claims data analysis. Dis Manag Health Outcomes. 2005;13:405-412.
14. Nurmagambetov T, Atherly A, Williams S, Holguin F, Mannino DM, Redd SC. What is the cost to employers of direct medical care for chronic obstructive pulmonary disease? COPD. 2006;3:203-209.
15. Halpin DMG, Miravitlles M. Chronic obstructive pulmonary disease: the disease and its burden to society. Proc Am Thorac Soc. 2006;3:619-623.
16. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Resp J. 2003;21:347-360.
17. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project. Clinical Classifications Software (CCS) for ICD-9-CM. Available at: www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
18. Mapel DW, Picchi MA, Hurley JS, et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest. 2000;117(5 Suppl 2):346S-353S.
19. Celli BR. The importance of spirometry in COPD and asthma. Chest. 2000;117(2 Suppl):15S-19S.
20. 1: the Lung Health Study. JAMA. 1994;272:1497-1505.
21. Friedman C, McKenna MT, Ahmed F, et al. Assessing the burden of disease among an employed population: implicalions for employer-sponsored prevention programs. J Occup Environ Med. 2004;46:3-9.
22. Javitz HS, Swan GE, Zbikowski SM, et al. Return on investment of different combinations of bupropion SR dose and behavioral treatment for smoking cessation in a health care setting: an employer's perspective. Value Health. 2004;7:535-543.
23. National Heart, Lung, and Blood Institute, World Health Organization. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (updated 2005). Available at: www.goldcopd.com. Accessed December 2005.
24. Friedman M, Menjoge SS, Anton SF, Kesten S. Healthcare costs with tiotropium plus usual care versus usual care alone following 1 year of treatment in patients with chronic obstructive pulmonary disorder (COPD). Pharmacoeconomics. 2004;22:741-749.
25. Friedman M, Hilleman DE. Economic burden of chronic obstructive pulmonary disease: impact of new treatment options. Pharmacoeconomics. 2001;19:245-254.